Skip to main content

Meritxell Ventura Cots

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Meritxell Ventura Cots

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

Efectos de la administración de albúmina en pacientes cirròticos con encefalopatia hepática

IP: Joan Genescà Ferrer
Collaborators: Meritxell Ventura Cots, Macarena Simon-Talero Horga
Funding agency: Instituto de Salud Carlos III
Funding: 242000
Reference: ICI14/00352
Duration: 01/01/2015 - 30/06/2019

Malalties Hepatobiliars (GRC)

IP: Rafael Esteban Mur
Collaborators: Beatriz Minguez Rosique, Immaculada Raurell Saborit, Lluís Viladomiu Catà, Antonio González Fernández, Lluis Castells Fusté, Maria del Mar Riveiro Barciela, Francisco Rodríguez Frias, Silvia Sauleda Oliveras, Victor Manuel Vargas Blasco, Maria Buti Ferret, Torrens Buscató, Maria Margarita, Josep Quer Sivila, Josep Gregori Font, Maria Nieves Martell Pérez-Alcalde, Damir Garcia Cehic, Juan Ignacio Esteban Mur, Meritxell Ventura Cots, Macarena Simon-Talero Horga, Joan Genescà Ferrer, David Tabernero Caellas
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 65000
Reference: 2014 SGR 421
Duration: 01/01/2014 - 31/12/2016

Progresión de la hipertensión portal: papel del microbioma intestinal como mediador del efecto de la obesidad

IP: -
Collaborators: Victor Manuel Vargas Blasco, Torrens Buscató, Maria Margarita, Meritxell Ventura Cots, Macarena Simon-Talero Horga
Funding agency: Instituto de Salud Carlos III
Funding: 98615
Reference: PI14/00331
Duration: 01/01/2015 - 31/12/2017

Recerca clínica i traslacionals de les complicacions de la cirrosi hepàtica

IP: Rafael Esteban Mur
Collaborators: Meritxell Ventura Cots
Funding agency: Instituto de Salud Carlos III
Funding: 72000
Reference: CM11/00171
Duration: 03/01/2012 - 02/01/2014

Related news

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

The research team used nanotechnology to deliver the drug directly to liver cells, which eliminated side effects without reducing effectiveness.

Related professionals

Lorena Villa García

Lorena Villa García

Predoctoral researcher
Research on Aging, Frailty and Transitions in Barcelona
Read more
Ana Gallego Cortes

Ana Gallego Cortes

Predoctoral researcher
Infectious Diseases
Read more
Maider Arando Lasagabaster

Maider Arando Lasagabaster

Infectious Diseases
Read more
Joaquin Castillo Justribo

Joaquin Castillo Justribo

Postdoctoral researcher
Clinical Neuroimmunology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.